Repositioning Candidates
Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
1608 records.
Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
---|---|---|---|---|---|---|
R1501 | DB13915 | approved | biotech | Axicabtagene ciloleucel | Therapeutic strategy associated | Details |
R1502 | DB13919 | experimental | small molecule | Candesartan | Target associated | Details |
R1503 | DB13931 | approved | small molecule | Netarsudil | Therapeutic strategy associated | Details |
R1504 | DB13944 | approved | small molecule | Testosterone enanthate | Indication associated | Details |
R1505 | DB13949 | approved | small molecule | Ferric cation | Therapeutic strategy associated | Details |
R1506 | DB13973 | approved; investigational | biotech | Remestemcel-L | Therapeutic strategy associated | Details |
R1507 | DB13975 | experimental | biotech | Black cohosh | Therapeutic strategy associated | Details |
R1508 | DB14001 | approved; nutraceutical; vet_approved | small molecule | alpha-Tocopherol succinate | Therapeutic strategy associated | Details |
R1509 | DB14002 | approved; nutraceutical; vet_approved | small molecule | D-alpha-Tocopherol acetate | Therapeutic strategy associated | Details |
R1510 | DB14003 | approved | small molecule | alpha-Tocopherol acetate | Therapeutic strategy associated | Details |
R1511 | DB14004 | approved; investigational | biotech | Tildrakizumab | Therapeutic strategy associated | Details |
R1512 | DB14006 | approved; nutraceutical | small molecule | Choline salicylate | Therapeutic strategy associated | Details |
R1513 | DB14009 | experimental; investigational | biotech | Medical Cannabis | Target associated | Details |
R1514 | DB14011 | investigational | small molecule | Nabiximols | Target associated | Details |
R1515 | DB14012 | approved; investigational | biotech | Burosumab | Indication associated | Details |
R1516 | DB14034 | experimental | small molecule | Darglitazone | Target associated | Details |
R1517 | DB14059 | experimental; investigational | small molecule | SC-236 | Therapeutic strategy associated | Details |
R1518 | DB14487 | approved; investigational | small molecule | Zinc acetate | Therapeutic strategy associated | Details |
R1519 | DB14502 | approved | small molecule | Sodium phosphate, dibasic | Indication associated | Details |
R1520 | DB14503 | approved | small molecule | Sodium phosphate, monobasic, unspecified form | Indication associated | Details |
R1521 | DB14507 | approved | small molecule | Lithium citrate | Indication associated | Details |
R1522 | DB14512 | approved; investigational; vet_approved | small molecule | Mometasone furoate | Therapeutic strategy associated | Details |
R1523 | DB14513 | approved; experimental; investigational | small molecule | Magnesium | Indication associated | Details |
R1524 | DB14533 | approved; investigational | small molecule | Zinc chloride | Therapeutic strategy associated | Details |
R1525 | DB14538 | experimental; vet_approved | small molecule | Hydrocortisone aceponate | Therapeutic strategy associated | Details |
R1526 | DB14539 | approved; vet_approved | small molecule | Hydrocortisone acetate | Therapeutic strategy associated | Details |
R1527 | DB14540 | approved; vet_approved | small molecule | Hydrocortisone butyrate | Therapeutic strategy associated | Details |
R1528 | DB14541 | approved; investigational; vet_approved | small molecule | Hydrocortisone cypionate | Therapeutic strategy associated | Details |
R1529 | DB14542 | approved; vet_approved | small molecule | Hydrocortisone phosphate | Therapeutic strategy associated | Details |
R1530 | DB14543 | approved; vet_approved | small molecule | Hydrocortisone probutate | Therapeutic strategy associated | Details |
R1531 | DB14544 | approved; vet_approved | small molecule | Hydrocortisone valerate | Therapeutic strategy associated | Details |
R1532 | DB14569 | approved; investigational | small molecule | Tedizolid | Indication associated | Details |
R1533 | DB14597 | approved; investigational | biotech | Lanadelumab | Therapeutic strategy associated | Details |
R1534 | DB14631 | approved; vet_approved | small molecule | Prednisolone phosphate | Therapeutic strategy associated | Details |
R1535 | DB14635 | experimental | small molecule | Curcumin sulfate | Therapeutic strategy associated | Details |
R1536 | DB14644 | approved | small molecule | Methylprednisolone hemisuccinate | Therapeutic strategy associated | Details |
R1537 | DB14669 | approved; vet_approved | small molecule | Betamethasone phosphate | Therapeutic strategy associated | Details |
R1538 | DB14683 | experimental | small molecule | Prezatide copper | Therapeutic strategy associated | Details |
R1539 | DB14684 | approved | small molecule | Calcium polycarbophil | Indication associated | Details |
R1540 | DB14731 | approved; investigational | biotech | Tagraxofusp | Therapeutic strategy associated | Details |
R1541 | DB14751 | approved | biotech | Mecasermin rinfabate | Indication associated | Details |
R1542 | DB14762 | approved; investigational | biotech | Risankizumab | Therapeutic strategy associated | Details |
R1543 | DB14783 | approved; investigational | small molecule | Diroximel fumarate | Therapeutic strategy associated | Details |
R1544 | DB14811 | approved; investigational | biotech | Isatuximab | Therapeutic strategy associated | Details |
R1545 | DB14845 | approved; investigational | small molecule | Filgotinib | Therapeutic strategy associated | Details |
R1546 | DB14901 | approved; investigational | biotech | Inclisiran | Indication associated | Details |
R1547 | DB14960 | approved | biotech | Somatrogon | Therapeutic strategy associated | Details |
R1548 | DB14962 | approved; investigational | biotech | Trastuzumab deruxtecan | Therapeutic strategy associated | Details |
R1549 | DB14967 | approved; investigational | biotech | Margetuximab | Therapeutic strategy associated | Details |
R1550 | DB14999 | approved; investigational | biotech | Human interferon beta | Therapeutic strategy associated | Details |
R1551 | DB15011 | approved; investigational | small molecule | Avacopan | Therapeutic strategy associated | Details |
R1552 | DB15021 | investigational | small molecule | Leriglitazone | Target associated | Details |
R1553 | DB15044 | approved; investigational | biotech | Tafasitamab | Therapeutic strategy associated | Details |
R1554 | DB15090 | approved; investigational | biotech | Tezepelumab | Therapeutic strategy associated | Details |
R1555 | DB15091 | approved; investigational | small molecule | Upadacitinib | Therapeutic strategy associated | Details |
R1556 | DB15119 | approved; investigational | biotech | Ropeginterferon alfa-2b | Therapeutic strategy associated | Details |
R1557 | DB15226 | approved; investigational | biotech | Dasiglucagon | Indication associated | Details |
R1558 | DB15303 | investigational | biotech | Faricimab | Therapeutic strategy associated | Details |
R1559 | DB15354 | approved; investigational | biotech | Evinacumab | Indication associated | Details |
R1560 | DB15442 | approved; investigational | small molecule | Trilaciclib | Therapeutic strategy associated | Details |
R1561 | DB15444 | approved; investigational | small molecule | Elexacaftor | Therapeutic strategy associated | Details |
R1562 | DB15456 | approved; investigational | small molecule | Vericiguat | Indication associated | Details |
R1563 | DB15495 | experimental | small molecule | Rocaglamide | Therapeutic strategy associated | Details |
R1564 | DB15496 | experimental | small molecule | Didesmethylrocaglamide | Therapeutic strategy associated | Details |
R1565 | DB15566 | approved; vet_approved | small molecule | Prednisolone acetate | Therapeutic strategy associated | Details |
R1566 | DB15595 | approved | biotech | Ebola Zaire vaccine (live, attenuated) | Therapeutic strategy associated | Details |
R1567 | DB15598 | approved | small molecule | Ferric maltol | Therapeutic strategy associated | Details |
R1568 | DB15661 | investigational | small molecule | Molnupiravir | Indication associated | Details |
R1569 | DB15699 | approved | biotech | Brexucabtagene autoleucel | Therapeutic strategy associated | Details |
R1570 | DB15719 | approved | biotech | Belantamab mafodotin | Therapeutic strategy associated | Details |
R1571 | DB15721 | investigational | biotech | Natural Killer Cell | Therapeutic strategy associated | Details |
R1572 | DB15724 | investigational | biotech | Human umbilical cord blood mononuclear cell-conditioned medium | Therapeutic strategy associated | Details |
R1573 | DB15726 | investigational | biotech | Human Umbilical Cord Mesenchymal Stem Cells | Therapeutic strategy associated | Details |
R1574 | DB15729 | investigational | biotech | Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins | Therapeutic strategy associated | Details |
R1575 | DB15730 | investigational | biotech | Placental Mesenchymal Stem Cells | Therapeutic strategy associated | Details |
R1576 | DB15731 | investigational | biotech | Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells | Therapeutic strategy associated | Details |
R1577 | DB15742 | investigational | biotech | MultiStem | Therapeutic strategy associated | Details |
R1578 | DB15745 | investigational | biotech | Washed Microbiota Transplantation | Therapeutic strategy associated | Details |
R1579 | DB15746 | investigational | biotech | Recombinant Human Plasma Gelsolin | Therapeutic strategy associated | Details |
R1580 | DB15750 | investigational | biotech | Trefoil Factor 2 | Therapeutic strategy associated | Details |
R1581 | DB15751 | investigational | biotech | MRx-4DP0004 | Therapeutic strategy associated | Details |
R1582 | DB15753 | investigational | biotech | Interferon Gamma | Therapeutic strategy associated | Details |
R1583 | DB15762 | approved | biotech | Satralizumab | Therapeutic strategy associated | Details |
R1584 | DB15866 | investigational | biotech | CK0802 | Therapeutic strategy associated | Details |
R1585 | DB15868 | investigational | biotech | Amniotic Epithelial Cells | Therapeutic strategy associated | Details |
R1586 | DB15869 | investigational | biotech | Platelet Lysate | Therapeutic strategy associated | Details |
R1587 | DB15890 | investigational | biotech | RAPA-501-Allo | Therapeutic strategy associated | Details |
R1588 | DB16028 | investigational | small molecule | Azemiglitazone | Target associated | Details |
R1589 | DB16157 | investigational | small molecule | Ensifentrine | Therapeutic strategy associated | Details |
R1590 | DB16165 | approved; investigational | small molecule | Finerenone | Therapeutic strategy associated | Details |
R1591 | DB16247 | investigational | biotech | Nangibotide | Therapeutic strategy associated | Details |
R1592 | DB16365 | investigational | small molecule | Treamid | Therapeutic strategy associated | Details |
R1593 | DB16366 | investigational | biotech | F-652 | Therapeutic strategy associated | Details |
R1594 | DB16367 | approved; investigational | biotech | Autologous peripheral blood-derived CD34+ cells | Therapeutic strategy associated | Details |
R1595 | DB16398 | investigational | biotech | Efmarodocokin alfa | Therapeutic strategy associated | Details |
R1596 | DB16416 | investigational | biotech | Vilobelimab | Therapeutic strategy associated | Details |
R1597 | DB16447 | investigational | small molecule | Thymoquinone | Therapeutic strategy associated | Details |
R1598 | DB16448 | investigational | biotech | CD24Fc | Therapeutic strategy associated | Details |
R1599 | DB16452 | investigational | small molecule | MAS825 | Therapeutic strategy associated | Details |
R1600 | DB16522 | investigational | small molecule | Sodium copper chlorophyllin | Therapeutic strategy associated | Details |